Patient characteristics
| Patient no. . | Sex . | Age at diagnosis, y . | Diagnosis . | Concomitant disease . | Type of antibody . | Hematologic values before rituximab treatment . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb level, g/dL . | Reticulocyte count, × 109/L . | Platelet count, × 109/L . | DAT . | IAT . | Transfusion dependence . | ||||||
| Responders | |||||||||||
| 1 | M | 0.3 | AIHA | — | Warm (IgG) | 6.6 | 390 | — | Pos | Pos | Yes |
| 2 | M | 0.3 | Evans | — | Warm (IgG) | 7.1 | 175 | 43 | Pos | Neg | No |
| 3 | F | 1.6 | AIHA | — | Negative | 7.8 | 230 | — | Neg | Neg | Yes |
| 4 | F | 1.8 | AIHA | — | Warm (IgG) | 10.0 | 210 | — | Pos | Pos | No |
| 5 | F | 1.9 | AIHA | Post-BMT | Warm (IgG) | 9.2 | 233 | — | Pos | Neg | No |
| 6 | F | 7.6 | Evans | Rheum arth | Warm (IgG) | 8.0 | 236 | 4 | Pos | Neg | No |
| 7 | F | 11.4 | AIHA | — | Warm (IgG) | 9.8 | 463 | — | Pos | Neg | No |
| 8 | F | 12.5 | Evans | Rheum arth | Warm (IgG) | 7.1 | 433 | 27 | Pos | Neg | No |
| 9 | M | 13.5 | AIHA | — | Warm (IgG) | 5.6 | 374 | — | Pos | Pos | No |
| 10 | F | 13.8 | AIHA | — | Warm (IgG) | 7.4 | 750 | — | Pos | Neg | No |
| Responders who relapsed | |||||||||||
| 11 | M | 1.3 | Evans | Vitiligo | Cold (IgM) | 9.3 | 185 | 61 | Pos | Neg | No |
| 12 | F | 1.3 | Evans | — | Warm (IgG) | 9.7 | 159 | 12 | Pos | Neg | No |
| 13 | F | 10.1 | AIHA | SLE | Warm (IgG) | 3.5 | 118 | — | Pos | Pos | Yes |
| Nonresponders | |||||||||||
| 14 | M | 1.1 | AIHA | — | Warm (IgG) | 6.9 | 240 | — | Pos | Pos | Yes |
| 15 | F | 13.6 | AIHA | — | Warm (IgG) | 7.7 | 428 | — | Pos | Neg | No |
| Median | 1.9 | 7.7 | 236 | 27 | |||||||
| Range | 0.3-13.8 | 3.5-10 | 118-750 | 4-61 | |||||||
| Patient no. . | Sex . | Age at diagnosis, y . | Diagnosis . | Concomitant disease . | Type of antibody . | Hematologic values before rituximab treatment . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb level, g/dL . | Reticulocyte count, × 109/L . | Platelet count, × 109/L . | DAT . | IAT . | Transfusion dependence . | ||||||
| Responders | |||||||||||
| 1 | M | 0.3 | AIHA | — | Warm (IgG) | 6.6 | 390 | — | Pos | Pos | Yes |
| 2 | M | 0.3 | Evans | — | Warm (IgG) | 7.1 | 175 | 43 | Pos | Neg | No |
| 3 | F | 1.6 | AIHA | — | Negative | 7.8 | 230 | — | Neg | Neg | Yes |
| 4 | F | 1.8 | AIHA | — | Warm (IgG) | 10.0 | 210 | — | Pos | Pos | No |
| 5 | F | 1.9 | AIHA | Post-BMT | Warm (IgG) | 9.2 | 233 | — | Pos | Neg | No |
| 6 | F | 7.6 | Evans | Rheum arth | Warm (IgG) | 8.0 | 236 | 4 | Pos | Neg | No |
| 7 | F | 11.4 | AIHA | — | Warm (IgG) | 9.8 | 463 | — | Pos | Neg | No |
| 8 | F | 12.5 | Evans | Rheum arth | Warm (IgG) | 7.1 | 433 | 27 | Pos | Neg | No |
| 9 | M | 13.5 | AIHA | — | Warm (IgG) | 5.6 | 374 | — | Pos | Pos | No |
| 10 | F | 13.8 | AIHA | — | Warm (IgG) | 7.4 | 750 | — | Pos | Neg | No |
| Responders who relapsed | |||||||||||
| 11 | M | 1.3 | Evans | Vitiligo | Cold (IgM) | 9.3 | 185 | 61 | Pos | Neg | No |
| 12 | F | 1.3 | Evans | — | Warm (IgG) | 9.7 | 159 | 12 | Pos | Neg | No |
| 13 | F | 10.1 | AIHA | SLE | Warm (IgG) | 3.5 | 118 | — | Pos | Pos | Yes |
| Nonresponders | |||||||||||
| 14 | M | 1.1 | AIHA | — | Warm (IgG) | 6.9 | 240 | — | Pos | Pos | Yes |
| 15 | F | 13.6 | AIHA | — | Warm (IgG) | 7.7 | 428 | — | Pos | Neg | No |
| Median | 1.9 | 7.7 | 236 | 27 | |||||||
| Range | 0.3-13.8 | 3.5-10 | 118-750 | 4-61 | |||||||
Evans indicates Evans syndrome; post-BMT, patient given allogeneic bone marrow transplantation for treatment of type 1 mucopolysaccharidosis; Rheum arth, rheumatoid arthritis; SLE, systemic lupus erythematosus; —, not applicable.